An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
UCB Pharma
ClinicalTrials.gov Identifier:
NCT00237458
First received: October 11, 2005
Last updated: April 16, 2012
Last verified: April 2012
  Purpose

This trial is the follow-on trial to a preceeding open-label trial which included patients with chronic refractory neuropathic pain. It is conducted at one site in the United Kingdom and the patient enrollment is completed. The patients had successfully completed the above mentioned trial and, in the investigator's opinion, would benefit from long-term administration of Lacosamide. After a 1-week run-in phase the patients were uptitrated to their optimal dose and then continued into the maintenance phase. Different pain qualities are assessed by a patient's diary.


Condition Intervention Phase
Chronic Refractory Neuropathic Pain
Drug: Lacosamide
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Resource links provided by NLM:


Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • Number of Subjects Reporting At Least 1 Treatment-Emergent Adverse Event (TEAE) During The Treatment Period. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 10 years) ] [ Designated as safety issue: No ]
  • Number of Subjects Withdrawing From Study Due To A Treatment-Emergent Adverse Event (TEAE) During The Treatment Period. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 10 years) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Within-Subject Change In Average Daily Pain Score During the Treatment Period. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 9 years) ] [ Designated as safety issue: No ]
    The Average Daily Pain Score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).

  • Within-Subject Change In The Perception Of Each Of The Individual Cardinal Symptoms of Pain During The Treatment Period - Shooting. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 9 years) ] [ Designated as safety issue: No ]
    Each individual cardinal symptom of pain is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst possible pain).

  • Within-Subject Change In The Perception Of Each Of The Individual Cardinal Symptoms of Pain During The Treatment Period - Burning. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 9 years) ] [ Designated as safety issue: No ]
    Each individual cardinal symptom of pain is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst possible pain).

  • Within-Subject Change In The Perception Of Each Of The Individual Cardinal Symptoms of Pain During The Treatment Period - Paraesthesiae. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 9 years) ] [ Designated as safety issue: No ]
    Each individual cardinal symptom of pain is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst possible pain).

  • Within-Subject Change In The Perception Of Each Of The Individual Cardinal Symptoms of Pain During The Treatment Period - Numbness. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 9 years) ] [ Designated as safety issue: No ]
    Each individual cardinal symptom of pain is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst possible pain).

  • Within-Subject Change In The Perception Of Each Of The Individual Cardinal Symptoms of Pain During The Treatment Period - Allodynia. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 9 years) ] [ Designated as safety issue: No ]

    Each individual cardinal symptom of pain is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst possible pain).

    Allodynia is defined as neuropathic pain caused by normally innocuous stimuli becoming painful.


  • Subject's Global Impression of Change In Pain During The Treatment Period. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 9 years) ] [ Designated as safety issue: No ]

    The Subject's Global Impression of Change is a self-evaluation by the subject of their overall change in relief of neuropathic pain since the beginning of the study rated on a 7-point scale ranging from:

    1. Much better
    2. Moderately better
    3. Mildly better
    4. No change
    5. Mildly worse
    6. Moderately worse
    7. Much worse

  • Investigator's Global Impression of Change In Pain During The Treatment Period. [ Time Frame: From Baseline Visit to Final Week of Treatment (approximately 9 years) ] [ Designated as safety issue: No ]

    The Investigator's Global Impression of Change is a physician's assessment of the patient's overall change in relief of neuropathic pain since the beginning of the study rated on a 7-point scale ranging from:

    1. Much better
    2. Moderately better
    3. Mildly better
    4. No change
    5. Mildly worse
    6. Moderately worse
    7. Much worse

  • Percentage of Days With Concomitant Pain ("Rescue") Medications Taken During Baseline Phase. [ Time Frame: Baseline Period (approximately 1 week) ] [ Designated as safety issue: No ]

    The percentage of days where rescue medication was taken is summarized by visit and by Treatment Phase (Baseline, Titration, and Titration + Treatment).

    The percentage of days of rescue medication use is defined as the number of days observed within the visit/study phase with rescue medication divided by the number of days in the visit/study phase times 100 for subjects who had taken the rescue medication.

    Summary statistics include mean and standard deviation.


  • Percentage of Days With Concomitant Pain ("Rescue") Medications Taken During Titration Phase. [ Time Frame: Titration Period (approximately 6 weeks) ] [ Designated as safety issue: No ]

    The percentage of days where rescue medication was taken is summarized by visit and by Treatment Phase (Baseline, Titration, and Titration + Treatment).

    The percentage of days of rescue medication use is defined as the number of days observed within the visit/study phase with rescue medication divided by the number of days in the visit/study phase times 100 for subjects who had taken the rescue medication.

    Summary statistics include mean and standard deviation.


  • Percentage of Days With Concomitant Pain ("Rescue") Medications Taken During Titration and Treatment Phases. [ Time Frame: From Titration Phase through Treatment Phase (approximately 9 years) ] [ Designated as safety issue: No ]

    The percentage of days where rescue medication was taken is summarized by visit and by Treatment Phase (Baseline, Titration, and Titration + Treatment).

    The percentage of days of rescue medication use is defined as the number of days observed within the visit/study phase with rescue medication divided by the number of days in the visit/study phase times 100 for subjects who had taken the rescue medication.

    Summary statistics include mean and standard deviation.



Enrollment: 7
Study Start Date: May 2001
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lacosamide
Open-label active treatment
Drug: Lacosamide

Dosage: Lacosamide up to 400 mg/day;

Dosage form: Film-coated tablets;

Dosage Frequency and Duration: Two times per day; 9.5 years

Other Names:
  • SPM 927
  • Vimpat

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is informed and given ample time and opportunity to think about her/his participation in this extension trial and has given her/his written informed consent
  • Subject met all inclusion criteria defined in the SP611 trial with SPM927 at the time of enrollment into trial SP611
  • Subject has successfully completed trial SP611 and, in the investigator's opinion, would benefit from long-term administration of SPM927
  • Subject is willing and able to comply with all trial requirements, including the ability to complete trial questionnaires

Exclusion Criteria:

  • Subject previously participated in this trial
  • Subject has participated in another trial of an investigational drug within the last 3 months (excluding trial SP611) or is currently participating in another trial of an investigational drug
  • Subject has had prior therapy with a Nonsteroidal Anti-inflammatory Drug (NSAID) or Anti-epileptic Drug (AED) within 28 days prior to the Eligibility Visit
  • Subject has evidence or history of significant Cardiovascular Disease within 12 months prior to the Eligibility Visit
  • Subject has laboratory values, which are outside the normal range and judged by the Investigator to be clinically significant
  • Subject has abnormal Renal or Hepatic function
  • Subject has a history of Malignancies with the exception of subjects with a documented disease-free interval of 5 years or more
  • Subject has a history of chronic alcohol or drug abuse within the last 12 months
  • Subject has any medical or psychiatric condition which, in the opinion of the Investigator, could jeopardize or compromise the subject's ability to participate in this continuation trial
  • Subject with a known history of severe Anaphylactic Reaction and/or serious or life threatening Blood Dyscrasias
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00237458

Locations
Germany
Monheim, Germany
Sponsors and Collaborators
UCB Pharma
Investigators
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
  More Information

Additional Information:
Publications:
Responsible Party: UCB Pharma
ClinicalTrials.gov Identifier: NCT00237458     History of Changes
Other Study ID Numbers: SP647
Study First Received: October 11, 2005
Results First Received: March 7, 2012
Last Updated: April 16, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Neuralgia
Pain
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Lacosamide
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 16, 2014